Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
detorubicin
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Detorubicin is a semisynthetic anthracycline, specifically the 14-diethoxyacetoxy ester of daunorubicin. It functions as an active anthracycline antineoplastic agent, demonstrating activity in previously untreated patients with metastatic melanoma. Its general toxicities, including cardiac toxicity, are noted to be similar to those of Adriamycin (doxorubicin).
- Other names
- semisynthetic 14-diethoxyacetoxy ester of daunorubicinsemisynthetic14-diethoxyacetoxy ester of daunorubicinsemisynthetic-14-diethoxyacetoxy ester of daunorubicin
02
Targets
TOP2A (DNA topoisomerase II)DNA
Beyond the preview
Go deeper on detorubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on detorubicin.